Neoadjuvant Chemotherapy Docetaxel With or Without SELUMETINIB in Patients With Triple Negative Breast Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to increase survival of patients with early and locally advanced
triple-negative breast cancer adding selumatinib to standard preoperative chemotherapy
regimen.